Is CJC-1295 Safe? Safety Profile 2026 — PeptidePrices

Q: Is CJC-1295 safe?

CJC-1295 has a safety rating of 7/10 in our methodology — good. Studied in human PK trials; well-tolerated; water retention, tingling reported; short-acting

Q: Is CJC-1295 FDA approved?

FDA status: Not FDA-approved. PeptidePrices does not sell or recommend any compound for human use; this information is for research-context only.

Q: Where can I find verified CJC-1295?

PeptidePrices tracks live prices and COA verification status across 30+ vendors. See our cheapest CJC-1295 listings for prices ranked by COA tier and $/mg.

Safety Profile

CJC-1295

Updated today

Secretagogue Peptide

7/10Good

How we score compound safety →

Primary use: Growth hormone secretagogue research

Regulatory Status

Not FDA-approved

Safety Summary

Studied in human PK trials
well-tolerated
water retention, tingling reported
short-acting

CJC-1295's 7/10 rating reflects mixed evidence — some clinical data and a meaningful research base, but enough open questions that researchers should weight personal risk tolerance heavily. Long-term safety in the population segment most likely to use this compound (off-label) is the area with the thinnest published evidence. Researchers often consider Ipamorelin and Tesamorelin as alternatives in the same category — see the related-compounds section below for safety comparisons.

Molecular Profile

TypeGHRH analog + GH secretagogue blend

Storage

Lyophilized−20°C, stable

Reconstituted2–8°C, within 14–30 days

Protect from light
Use bacteriostatic water

Related Compounds

Methodology

How we rate peptide safety

Every compound in our index gets a 1–10 safety score based on four weighted factors. The score reflects known research-use risk — not medical advice.

40% — Clinical evidence. Volume of peer-reviewed trials, sample sizes, duration, and consistency of outcomes. FDA-approved compounds anchor the top end (8–10); preclinical-only compounds cap at 6.
30% — Adverse-event profile. Severity and frequency of reported side effects, including GI events, cardiovascular signals, hypoglycemia, and long-term organ effects.
20% — Regulatory status. FDA approval, EMA approval, or status in active clinical trials. Compounds under safety warnings are penalized.
10% — Community-reported outcomes. Reddit, forum, and published case-report signal beyond formal trials. Used as a late-stage tiebreaker, not a leading factor.

9–10Well-studied, FDA-approvedLarge-trial evidence, established long-term safety. Examples: semaglutide, tesamorelin at approved doses.

7–8Mostly safe, some caveatsPhase 2/3 evidence or long community track record with known manageable side effects. Routine monitoring recommended.

5–6Mixed dataLimited clinical trials, mostly community/preclinical data. Real but uncertain risk profile.

3–4Caution advisedKnown side-effect patterns, thin safety data, or compounds under active regulatory scrutiny.

1–2Significant risk signalsDocumented serious adverse events (cardiovascular, hepatotoxicity, contamination) or withdrawn regulatory status.

Related compounds

Other compounds researchers compare with CJC-1295

Full CJC-1295 profile Cheapest CJC-1295 deals

Safety ratings are derived from published clinical data, FDA approval status, and community-reported outcomes. They are not medical advice. Always consult a healthcare professional before using any research compound.